785 articles
Neuvasq's preclinical antibodies target Wnt signaling to reverse retinal damage, offering a potential disease-modifying leap beyond current eye injections.
SimonMed is expanding AI imaging tools that extract cardiovascular, bone, and spine risk data from scans patients already get.
Twenty global teams win funding and data access to find new ALS drug targets using AI and multi-omics — a potential model for all aging diseases.
A biotech firm's preclinical data shows an IV-delivered gene therapy can reach the brain and silence tau — no invasive procedure required.
Pegsebrenatide, a long-acting GLP-1 receptor agonist, is now in human trials targeting neurodegeneration in progressive MS — with broad longevity implications.
Epigenetic clock pioneer Steve Horvath explains why the field is converging on validated biomarkers to make longevity medicine actionable.
From a massive family study of centenarians to a paradigm shift in how aging is measured, longevity science is evolving fast.
Buck Institute scientist engineers CAR-Treg cells to detect amyloid plaques and release Alzheimer's antibody exactly where needed.
A 40,000-person study found daily egg eaters aged 65+ had up to 27% lower Alzheimer's risk, with even modest intake showing brain benefits.
New research reveals GLP-1 drugs like Ozempic deliver stronger results for 'see-food' eaters than those who eat due to stress or emotions.
A clinical trial found testosterone gel plus exercise prevented visceral fat increases in women over 65 recovering from hip fractures.
Biotin supplements taken by cancer patients for hair loss can distort key blood markers, potentially masking cancer recurrence or delaying treatment.
